Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von fchar99 

Insmed Inc. diskutieren

Insmed Inc.

WKN: A1JJA3 / Symbol: INSM / Name: Insmed / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

165,00 €
-0,60 %

Einschätzung Buy
Rendite (%) 115,38 %
Kursziel 102,54
Veränderung
Endet am 19.02.26

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Wells Fargo & Company from $85.00 to $107.00. They now have an "overweight" rating on the stock.
Ratings data for INSM provided by MarketBeat

Insmed Incorporated (NASDAQ: INSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 116,77 %
Kursziel 85,90
Veränderung
Endet am 21.02.26

Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 116,77 %
Kursziel 91,56
Veränderung
Endet am 21.02.26

Insmed Incorporated (NASDAQ: INSM) had its price target lowered by analysts at Stifel Nicolaus from $97.00 to $96.00. They now have a "buy" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 116,77 %
Kursziel 103,20
Veränderung
Endet am 21.02.26

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Truist Financial Co. from $105.00 to $108.00. They now have a "buy" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 121,05 %
Kursziel 95,22
Veränderung
Endet am 25.02.26

Insmed Incorporated (NASDAQ: INSM) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $100.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 127,03 %
Kursziel 96,10
Veränderung
Endet am 25.02.26

Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $101.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 134,97 %
Kursziel 91,44
Veränderung
Endet am 19.03.26

Insmed Incorporated (NASDAQ: INSM) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $100.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 131,72 %
Kursziel 88,03
Veränderung
Endet am 20.03.26

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Bank of America Co. from $92.00 to $96.00. They now have a "buy" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 170,97 %
Kursziel 78,30
Veränderung
Endet am 22.04.26

Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 173,17 %
Kursziel 80,17
Veränderung
Endet am 12.05.26

Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 166,67 %
Kursziel 94,53
Veränderung
Endet am 13.05.26

Insmed Incorporated (NASDAQ: INSM) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $105.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Insmed Incorporated (NASDAQ: INSM) was upgraded by analysts at Citigroup Inc. to a "buy" rating.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 111,32 %
Kursziel 100,97
Veränderung
Endet am 10.06.26

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Leerink Partners from $100.00 to $115.00. They now have an "outperform" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 111,32 %
Kursziel 105,18
Veränderung
Endet am 11.06.26

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at HC Wainwright from $90.00 to $120.00. They now have a "buy" rating on the stock.
Ratings data for INSM provided by MarketBeat

Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc..
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 111,32 %
Kursziel 104,30
Veränderung
Endet am 11.06.26

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Wells Fargo & Company from $107.00 to $119.00. They now have an "overweight" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 111,32 %
Kursziel 95,54
Veränderung
Endet am 11.06.26

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Bank of America Co. from $94.00 to $109.00. They now have a "buy" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 94,22 %
Kursziel 89,40
Veränderung
Endet am 11.06.26

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Morgan Stanley from $90.00 to $102.00. They now have an "overweight" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 94,22 %
Kursziel 92,91
Veränderung
Endet am 11.06.26

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Royal Bank of Canada from $99.00 to $106.00. They now have an "outperform" rating on the stock.
Ratings data for INSM provided by MarketBeat